key: cord-0332534-qzedpz8u authors: Wang, Eric; Chakraborty, Arup K. title: Design of immunogens for eliciting antibody responses that may protect against SARS-CoV-2 variants date: 2022-01-25 journal: bioRxiv DOI: 10.1101/2022.01.24.477469 sha: cd464087af31e2392d826e47fc0a50a91f83d17e doc_id: 332534 cord_uid: qzedpz8u The rise of SARS-CoV-2 variants and the history of outbreaks caused by zoonotic coronaviruses point to the need for next-generation vaccines that confer protection against variant strains. Here, we combined analyses of diverse sequences and structures of coronavirus spikes with data from deep mutational scanning to design SARS-CoV-2 variant antigens containing the most significant mutations that may emerge. We trained a neural network to predict RBD expression and ACE2 binding from sequence, which allowed us to determine that these antigens are stable and bind to ACE2. Thus, they represent viable variants. We then used a computational model of affinity maturation (AM) to study the antibody response to immunization with different combinations of the designed antigens. The results suggest that immunization with a cocktail of the antigens is likely to promote evolution of higher titers of antibodies that target SARS-CoV-2 variants than immunization or infection with the wildtype virus alone. Finally, our analysis of 12 coronaviruses from different genera identified the S2’ cleavage site and fusion peptide as potential pan-coronavirus vaccine targets. Vaccines that protect against severe acute respiratory distress coronavirus 2 (SARS-CoV-2) are 25 highly effective. However, variants that impact vaccine efficacy are emerging. For example, the Moreover, other pathogenic coronaviruses could evolve in the future due to zoonosis. Thus, vac-34 cines that protect against potential SARS-CoV-2 variants and those that protect against potential 35 zoonotic coronaviruses would be beneficial for curtailing future outbreaks. is located in the S1 domain and is responsible for facilitating viral entry by binding to angiotensin-39 converting enzyme 2 (ACE2) (Zamorano Cuervo and Grandvaux (2020)). Following ACE2 binding, 40 most effective at protecting against a particular strain. However, a vaccine that adequately pro-90 tects a population when diverse new variants emerge can serve as a shield and provide time for 91 a strain-specific vaccine to be developed. Our results also highlight factors that impact titers such 92 as previous exposure to WT antigen and the fraction of GC-seeding cells that are memory cells 93 generated during past exposure. Finally, by applying the conservation analysis to 12 diverse coro-94 naviruses, we identify the S2' cleavage site and fusion peptide as conserved regions, pointing to a 95 potential target for a pan-coronavirus vaccine. In order to identify conserved and variable residues in coronavirus spike proteins, we leveraged 99 both sequence and structural data. Structural data can be used to determine structural conserva-100 tion (as described below) in a way that does not strongly depend on the number of insertions or 101 deletions. In our method, each residue of the spike was assigned a conservation fraction ranging 102 from 0 to 1, which was the average of the structural conservation fraction and the biochemical 103 conservation fraction. An overview of the method that we use to determine these conservation 104 scores is provided in Figure 1 . Using the structures for the trimeric spike of various coronaviruses (Table S1 ), atoms were removed 107 from each trimer so that only a monomer remained. Thus, the structural conservation fraction was 108 calculated using a monomer rather than the full trimer, but the monomer retained the conforma- This process identified residues across different coronavirus spikes that structurally overlap in the 116 alignment. This data was used to construct a structure-based sequence alignment. A table is first 117 constructed (see Figure 1 ) where the residues of the spike proteins are the rows, the column names 118 correspond to coronaviruses (such as MHV, HKU1, and HKU2), and the entries of the table are the 119 20 amino acids or a placeholder entry of "." The placeholder entry of "." means that the coronavirus 120 spike protein was not able to align at that residue. 121 The structural conservation fraction was calculated from the structure-based sequence align-122 ment using a particular coronavirus as a reference. For each residue, the structural conservation 123 fraction was the fraction of other coronaviruses that are able to structurally align at that residue. 124 We illustrate this with an example from Figure 1's table, assuming for simplicity that the first row 125 corresponds to residue 1. If we select residue 1 and MHV as a reference coronavirus, the other 126 coronaviruses are HKU1 and HKU2. Only HKU1 is able to structurally align, so the structural con-127 servation fraction is 0.5. It is also possible that the reference coronavirus did not align at the chosen 128 residue, in which case the structural conservation fraction is 0. For example, consider residue 1 us-129 ing HKU2 as a reference coronavirus. Since the entry is ".", then the structural conservation fraction For each coronavirus, a set of several hundred spike sequences were gathered (a complete list of se-133 quences is available at https://github.com/ericzwang/sars2-vaccine/tree/main/data/aligned-cov-sequences. The biochemical conservation fraction was calculated from the multiple sequence alignment 138 using a particular coronavirus as a reference. For each residue, the biochemical conservation frac-139 tion was the fraction of sequences that have an amino acid in the same class (hydrophobic, polar, 140 positive, or negative) as the reference coronavirus's consensus (most common) amino acid. Thus, 141 this calculation tolerates mutations if they are biochemically similar. To illustrate this procedure using Figure 1 figure supplement 1, assuming that the first row 143 corresponds to residue 1 for simplicity, suppose we wish to calculate the biochemical conservation 144 fraction of residue 1 using MHV as a reference coronavirus. The consensus amino acid from the 145 MHV alignment is F, which is a hydrophobic amino acid. The biochemical conservation fraction is 146 the fraction of amino acids in the first row of the concatenated alignment that are also hydrophobic. The conservation fraction was the average of the structural conservation fraction and the biochem-149 ical conservation fraction. For the design of antigens that may protect against SARS-CoV-2 variants, 150 only SARS and SARS-CoV-2 data were considered. Since SARS and SARS-CoV-2 are closely related, 151 the threshold conservation fraction below which a residue was identified as variable was chosen 152 to be 0.99. For pan-coronavirus vaccine target identification, we considered 12 coronaviruses from differ-154 ent genera (Table S1) , which constituted an analysis of 12 spike protein structures and ∼4000 spike 155 protein sequences. We set a threshold conservation fraction of 0.8, which was chosen because it 156 was the largest value at which we observed a conserved region comparable in size to an antibody of mutations (with respect to the wildtype Wuhan SARS-CoV-2 sequence) that satisfied the follow-168 ing criteria: 169 1. The mutation was in a residue determined to be variable using the calculation outlined in 170 Section 2.1. The structure and sequence data were restricted to SARS-CoV-2 and SARS, and 171 the conservation fraction threshold was set to 0.99. SARS was included because a calculation 172 exclusively using the structures of SARS-CoV-2 variants and ∼300,000 SARS-CoV-2 sequences 173 classified nearly the entire spike protein as conserved (Figure 7 figure supplement 1) . In other 174 words, only a few SARS-CoV-2 mutations have occurred in current SARS-CoV-2 variants, so we 175 consider residues that are different in SARS as such mutations have the potential to emerge 176 because these viruses are closely related. The Omicron variant emerged after our analyses 177 were completed, but its characteristics support our use of SARS data. We considered the 15 178 RBD mutations in the Omicron variant, and found that 12 out of 15 Omicron RBD mutations 179 are classified as variable residues according to our calculation. Additionally, all RBD muta-180 tions in previous variants (Alpha, Beta, Delta, Gamma) are considered variable. Therefore, 181 while few SARS-CoV-2 mutations have already emerged, our choice of including SARS data 182 appears to be predictive of mutations that may emerge in the future. stability. A threshold on the change in expression from the WT (expressed as log 10 (MFI)) was 187 set to -0.2, which was chosen such that mutations in circulating variants would be considered 188 viable. At this stage, multiple-mutation effects were not considered, but they were considered 189 when the final antigens were evaluated using the expression-prediction neural network we An example of a prevalent non-escape mutation is N501Y, which first appeared in the Alpha 213 variant and increased ACE2 binding affinity without significantly affecting antibody binding. Although some of the 34 escape mutations have not arisen yet, they may arise in the future as 215 natural and vaccine-induced responses impose selection pressures. So, they were included 216 in our antigens in order to protect against future variants. Indeed, Q493R, one of the most sig-217 nificant class 1/2 escape mutations in the Omicron variant, is found among these 34 escape 218 mutations and has not appeared in previous variants of concern. Note again that Omicron 219 emerged after we completed our analyses. The procedure outlined above resulted in a set of mutations that were in variable residues and 221 would likely abrogate binding to neutralizing class 1 and 2 antibodies circulating in vaccinated and 222 naturally infected persons, and did not diminish ACE2 binding or decrease spike stability and so 223 would likely be viable viruses. This list of mutations are candidates for inclusion in antigens that 224 may elicit a broadly protective polyclonal antibody response. 225 Additionally, a survey of ∼300,000 SARS-CoV-2 sequences from the GISAID database (sequences 226 available at https://github.com/ericzwang/sars2-vaccine/tree/main/data/gisaid_RBD_sequences.tar. 227 gz) revealed several mutations prevalent in circulating strains. Among these, 3 mutations (K417T, 228 K417N, and T478K) were the most prevalent mutations that also escape antibodies, but they were 229 not among the 34 mutations with the largest escape fractions from deep mutational scanning. Nonetheless, these 3 mutations were also considered in order to protect against current circulating 231 variants. In total, the list contained 37 mutations split among 10 residues. Multiple mutations from the list generated using the procedure described above were spatially 233 close together on the RBD. Multiple such mutations on the same RBD was undesirable as it could 234 lead to coupled effects that affect ACE2 binding or RBD stability. Although such effects were later 235 accounted for using the neural networks described in Section 2.3, the data used to train those 236 networks mostly contained RBDs with spatially separated mutations. So, we grouped the mutated 237 residues such that the residues within a group would be maximally separated in space on the RBD. To accomplish this, we divided the 10 mutated residues into all possible combinations of 2 groups 239 of 5 residues, and our goal was to select the combination with the maximum separation between 240 residues. This was accomplished as follows: 241 1. For a particular combination of two groups, two numbers, 1 and 2 , were calculated. To 242 determine 1 , consider the 5 residues in the first group positioned on the structure of the RBD. The centers of mass of the 5 residues formed a polygon, and the volume of that polygon was 2. The combination was assigned a score, which was calculated as the minimum of 1 and 2 248 (min( 1 , 2 )) 249 3. From all possible combinations, the combination with the largest value of min( 1 , 2 )) was 250 chosen. Selecting the score as min( 1 , 2 )), instead of 1 + 2 , avoided choosing cases with 251 severe imbalance between the groups, which may have deleteriously impacted the stability 252 of half of our antigens. For each of the two groups thus selected, we generated 3 sequences with 5 mutations per se-254 quence. Since there are 2 groups, there are 6 sequences total. For each residue, the amino acid 255 mutations were chosen starting from those with the largest escape fractions (thus, those that es-256 cape antibodies most). However, the mutations were also chosen such that the amino acids were 257 dissimilar, meaning that a potential mutation of the same class (hydrophobic, polar, positive, nega-258 tive) as a previously selected mutation was only selected if no dissimilar mutations were available. For example, if the mutation with the largest escape fraction at residue 490 was F490K, then the 260 first sequence used F490K. For the second sequence, the mutation with the second-largest escape 261 fraction at residue 490 was F490R. But, F490R was skipped because R and K are biochemically sim-262 ilar amino acids. The second sequence then moved to the mutation with the third-largest escape 263 fraction, which was F490E, and this mutation was used because E is not biochemically similar to K. This process repeated for the third sequence and then moved on to another residue. After all 5 265 residues in the first group were thus examined, the process was repeated for the 5 residues in the 266 second group. The published data for selecting stable mutations was based on single mutation effects (Starr et al. 272 (2020)), but the designed sequences possessed 5 mutations each. Therefore, it was not known 273 whether the designed sequences were still stable or maintained ACE2 binding. We noted that the 274 deep mutational scanning experiments provided two datasets -one with measured changes in 275 expression compared to WT for multi-mutant RBDs, and another with measured changes in ACE2 276 binding affinity compared to WT for multi-mutant RBDs. After removing sequences with no mu-277 tations or missing labels, the expression dataset contained ∼169,000 mutants with 1-7 mutations, 278 and the binding affinity dataset contained ∼135,000 mutants with 1-7 mutations. For the expression dataset, every sequence was one-hot encoded for the 20 amino acids, with 280 unmutated residues represented by a zero vector. This one-hot encoding matrix was element-wise 281 multiplied with a matrix of the single-mutation expression changes to yield a final matrix termed 282 the expression matrix. In one approach, single-mutation effects were assumed to be additive, 283 and the overall change in expression was the sum of the expression matrix. By training a neural 284 network on the dataset, additivity of single-mutations effects did not need to be assumed. The 285 network architecture is illustrated in Figure 2 . In this approach, the expression matrix was passed 286 into a 1D convolutional layer (32 filters, kernel size 3, same padding, and ReLu activation), a max 287 pooling layer (pool size of 2, stride of 1, and same padding), a 1D convolutional layer (16 filters, 288 kernel size 3, same padding, and ReLu activation), a max pooling layer (pool size of 2, stride of 289 1, and same padding), a flatten layer, a dense layer (64 neurons, ReLu activation), another dense 290 layer (32 neurons, ReLu activation), and an output layer of 1 neuron. 291 We performed 10-fold cross validation with a 90% train, 5% validation, and 5% test split. Opti- The same approach was used to train a separate network that predicted changes in ACE2 bind-298 ing affinity. The only differences were that the binding affinity network was trained using the bind-299 ing affinity dataset rather than the expression dataset, and the input matrix was the binding affinity 300 matrix instead of the expression matrix. The neural networks were then used to predict the expres- 303 We simulated the processes that occur during AM using a coarse-grained stochastic model in order 304 to study how antibodies develop in response to immunization with our designed antigens. An (2005)). This procedure allows identification of 315 RBD residues at the RBD-antibody interface with buried surface areas greater than 0 Å 2 . In order 316 to choose residues that were consistently part of the class 1 or class 2 epitope, only residues that 317 were bound by 3 or more class 1 or class 2 antibodies were included. Using the conservation analy-318 sis described above, 9 of the 50 residues had conservation fractions above 0.99 and were assigned 319 as conserved. The remaining 41 residues were assigned as variable. For a seeding B cell, each residue, k, was associated with a number PAR(k), which was initially 321 sampled from a uniform distribution between -0.18 and 0.90. After AM began, the value of PAR (k) 322 changed due to mutations, and the bounds on these values were -1 and 1.5. The epitope residues 323 were represented by a number EPI(k), with values of +1 for WT residues and negative values for 324 mutated residues depending on how biochemically different the mutated residue is from the WT. For a mutation in the same class (such as hydrophobic to hydrophobic), the epitope residue was 326 -1. For a mutation from hydrophobic to polar, polar to charged, or vice-versa, the epitope residue 327 was -2. For a mutation from hydrophobic to charged or vice-versa, the epitope residue was -3. For 328 a mutation from positively charged to negatively charged or vice-versa, the epitope residue was -4. To illustrate the construction of the epitope vector, we will use the Delta variant, which is defined 330 using the mutations L452R and T478K, as an example. L452R is a hydrophobic to positive mutation 331 (corresponding to a value of -3), and T478K is a polar to positive mutation (corresponding to a value 332 of -2). Therefore, one residue of the epitope vector will have a value of -3, another will have a value 333 of -2, and the remaining residues will have values of +1. The order of the residues does not matter 334 in our simple model. The binding free energy was calculated according to where PAR(k) was the paratope residue at position k and EPI(k) was the epitope residue at 337 position k. Essentially, the binding free energy is a dot product between the paratope and epitope in binding free energy for that residue was sampled from a shifted log-normal distribution: where was a standard normal random variable, was a shift parameter, was the mean of the In the light zone of the GC, B cells underwent selection based on their binding affinity to antigen. First, each B cell had a probability of successfully internalizing antigen according to where was a sum over all antigens that the B cell encounters, was the concentration of 365 antigen , was the binding free energy to antigen , was a reference free energy, and 366 was a scaling parameter. We used the same parameters as Sprenger et. al ( = 0.08, = 9 ). For a particular immunization scheme, the concentration that produces the highest antibody titers took values of either +1 or -1, and the probability that the residue is +1 was the conservation frac- which the mutations only occur in the 10 residues that are also mutated in the designed antigens. 423 We also considered panels in which mutated residues take on different values (-1, -2, -3, and -4). while the additive assumption is correlated to the overall change in expression or binding, using 435 network models offers a significant benefit. Since these neural networks achieve high correlations on test sets, we compared the predicted 437 expressions and binding affinities for our designed antigens to several circulating variants ( We then used our computational model of AM to study how antibodies develop in response to our 449 antigens as well as the WT spike protein. The goals were to identify vaccination schemes using 450 our antigens that may be best at protecting against variants compared to vaccination with the WT 451 spike alone, and to get mechanistic insights into the pertinent AM processes. 452 3.2.1 Reduced titers against SARS-CoV-2 variants following WT immunization 453 We simulate AM following one WT immunization, which models infection or one vaccine dose, and 454 two WT immunizations, which models two vaccine doses or infection followed by one vaccine dose. In Figure 4a , the anti-WT titers are high for one immunization (blue bars in various panels) and even 456 higher for two immunizations (orange bars in various panels). In contrast, the titers against vari- this coarse-grained model is not structurally detailed enough to recapitulate those differences. We then used our model to identify an optimal immunization scheme with our 6 designed anti-471 gens. We simulated a single immunization with all 6 antigens (Seq1-6), two immunizations with all 472 6 antigens (Seq1-6 | Seq1-6), a single immunization with sequences 1-3 (Seq1-3) and an immuniza-473 tion of sequences 1-3 followed by an immunization with sequences 4-6 (Seq1-3 | Seq4-6). We first which is expected because the cocktail antigens are mutated from the WT. However, the boosted 479 cocktails (Seq1-6 | Seq1-6 and Seq1-3 | Seq4-6) still retain moderately high titers against WT, in-480 dicating that they may still be protective. The immunizations that start with Seq1-3 (Seq1-3 and 481 Seq1-3 | Seq4-6) have slightly higher anti-WT titers than the analogous immunization starting with 482 Seq1-6 (Seq1-6 and Seq1-6 | Seq1-6). This is because the antigens in Seq1-6 are mutated across 10 483 residues while the antigens in Seq1-3 are mutated across 5 residues, so the antibodies resulting 484 from immunization with Seq1-3 will have more residues that resemble the WT sequence (more Anti-Seq1 titers are low following WT immunization because sequence 1 contains numerous 489 mutations. Seq1-6 immunization produces lower anti-Seq1 titers than Seq1-3 immunization be- For anti-Seq4 titers, immunization with Seq1-6 produces higher titers than immunization with 501 Seq1-3 because sequences 1-3 are all mutated in different residues from sequence 4. Immuniza-502 tion with Seq1-6 | Seq1-6 produces higher anti-Seq4 titers than immunization with Seq1-3 | Seq4-6, 503 which is somewhat unexpected because one might expect that a boost with Seq4-6 would produce 504 higher anti-Seq4 titers than a boost with Seq1-6. The origin of this result is that, because Seq 4-6 505 are very different from Seq 1-3, the memory B cells produced by priming with Seq 1-3 are poorly 506 adapted to Seq 4-6. Therefore, the boost with Seq4-6 results in many memory B cells in the sec-507 ondary GC dying (Figure 4 figure supplement 4) , which reduces the anti-Seq4 titer from the boost. immunization with Seq1-6 and Seq1-6 | Seq1-6. That is, vaccination using these schemes protects 531 against variants with up to 10 mutations in particular variable residues. The mean panel titers for 532 Seq1-3 | Seq4-6 do drop as the number of mutations increases, but less so than WT immunization. These results suggest that Seq1-6 | Seq1-6 may be an effective immunization scheme that could 534 protect against current variants and some that may emerge in the future. between the all-antigen and one-antigen case is that the optimal concentration is lower for the 541 all-antigen case (Figure 4 figure supplement 7 ). An optimal concentration exists because low con-542 centrations induce GC collapse while high concentrations are incapable of discriminating between 543 low-affinity and high-affinity clones. In the one-antigen case, a B cell that has high affinity to a particular antigen will likely survive a 545 cycle if it encounters that antigen on the FDC, but it will likely die if it encounters a different antigen and SARS to bind ACE2, while MERS binds DPP4 (Table S1 ). In contrast to this, the S2 domain of the spike possesses residues that are structurally conserved 616 across many coronaviruses. In particular, 9 out of 12 of the coronaviruses share a conserved patch 617 of residues in the S2 subunit despite coming from diverse lineages. For example, SARS-CoV-2 and 618 IBV both share this conserved region even though SARS-CoV-2 is a betacoronavirus that infects 619 humans and IBV is a gammacoronavirus that infects birds. These residues are conserved in many coronaviruses because they overlap with the S2' cleav- these antigens provides stronger protection against current variants and certain potential variants 652 than the WT vaccination does. In particular, a specific cocktail (sequence 1-6) is predicted to be 653 optimal. Our cocktail vaccination schemes result in lower titers for the WT antigen than vaccination with 655 the WT antigen alone. It is important to emphasize that our goal is to generate a response that is 656 protective against different variants that may emerge. Such a vaccine will be less protective for any 657 given variant compared to a strain-specific vaccine. However, a vaccine that provides adequate cov-658 erage to diverse potential variants would confer protection to a population, which may sufficiently 659 restrict transmission on its own or buy time for a strain-specific vaccine to be developed without 660 the need for strict non-pharmaceutical interventions. The antibodies elicited by our cocktail vaccine are not bnAbs as they are not designed to target 662 conserved regions. Our AM simulations suggest that the antibodies are broadly protective against 663 multiple mutations that occur in the residues that are mutated in the designed antigens, but not 664 against mutations that occur outside of those residues. Thus, variants that escape our cocktail 665 vaccine may arise. However, note that the residues mutated in the designed antigens are predicted 666 by our conservation analyses to be the most likely to emerge . Also, our AM model weights all 667 residues equally in order to calculate the binding free energy, which is a limitation of the model. In actuality, certain residues easily abrogate antibody binding upon mutation (specifically, class 669 1 and 2 antibodies elicited from exposure to the WT sequence), and these escape mutations are )). However, the 678 chimeras induced lower neutralizing titers against SARS-CoV-2 variants of concern than the WT 679 SARS-CoV-2 sequence. This is not surprising because the chimeras are designed using sarbecoviruses, 680 which are more mutated from the variants of concern than WT SARS-CoV-2 is. If one aims to pro-681 tect against just SARS-CoV-2 variants, the chimeric vaccine is not better than the WT SARS-CoV-2 682 vaccine. Our designed antigens are predicted to generate higher titers against SARS-CoV-2 variants 683 than the WT by exploiting data specifically for variants. Therefore, our antigens would be more ef-684 fective at addressing the immediate threat of vaccine-evading SARS-CoV-2 variants, while chimeric 685 sarbecovirus vaccines would be more effective at addressing the long-term threat of future sarbe-686 coviruses. Looking beyond sarbecoviruses, a vaccine that protects against any coronavirus would be bene- fectly conserved, so targeting it would likely yield a vaccine that is less effective against a particular 703 coronavirus than a strain-specific vaccine. Taken together, the bulk of our results predict that a specific cocktail of variant antigens used 705 as an immunogen would offer protection against variants of SARS-CoV-2 that may emerge in the 706 future. We hope that experimental efforts to test this prediction will follow. We also suggest one 707 vaccination scheme that may help protect against diverse coronaviruses. Spike structure colored by conservation fraction exclusively using SARS-CoV-2 data. Green residues have conservation fractions above 0.8, blue residues have conservation fractions below 0.8 and are not in the RBD, and red residues have conservation fractions below 0.8 and are in the RBD. PDB structures used to calculate the structural conservation fraction include the WT structure (PDB ID: 6VXX), the Alpha variant structure (PDB ID: 7LWI), the Beta variant structure (PDB ID: 7LWS), the Delta variant structure (PDB ID: 7V7Q), and the Gamma variant structure (PDB ID: 7M8K). ∼300,000 spike sequences were used to calculate the biochemical conservation fraction, which are available at https://github.com/ericzwang/sars2-vaccine/tree/main/data/ aligned-cov-sequences.gz. Effectiveness of the BNT162b2 Covid-19 Vaccine against the B.1.1.7 723 and B.1.351 Variants Viral surface geometry shapes influenza and coronavirus spike evolution through antibody pressure. 726 Biophysics Infection-and vaccine-induced antibody binding and neutralization of the B CoV-2 variant Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-785 CoV-2 B.1.617 Variants Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-790 CoV-2 B.1.617 Variants tory Syncytial Virus Infection and Disease Sequential Immunization Elicits Broadly Neutralizing Anti-HIV-1 Antibodies in Ig Knockin 798 Mechanisms underlying vaccination protocols that may optimally elicit broadly 801 neutralizing antibodies against highly mutable pathogens Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain that Escape 811 Antibody Recognition Deep learning with Keras Evolutionary relationships and sequence-structure determinants in human